Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
- Authors
- Lavie, D[Lavie, David]; Timmerman, J[Timmerman, John]; Sanz, RG[Sanz, Ramon Garcia]; Kim, WS[Kim, Won Seog]; Kim, TM[Kim, Tae Min]; Avigdor, A[Avigdor, Abraham]; Dierickx, D[Dierickx, Daan]; Jagadeesh, D[Jagadeesh, Deepa]; Molin, D[Molin, Daniel]; Ozcan, M[Ozcan, Muhit]; Sevindik, OG[Sevindik, Omur Gokmen]; Saeed, H[Saeed, Hayder]; Sidi, Y[Sidi, Yulia]; Pillai, P[Pillai, Pallavi]; Marinello, P[Marinello, Patricia]; Herrera, AF[Herrera, Alex Francisco]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.